Rhythm Pharmaceuticals (RYTM) EBT (2016 - 2026)

Rhythm Pharmaceuticals (RYTM) has 11 years of EBT data on file, last reported at -$55.1 million in Q1 2026.

• On a quarterly basis, EBT fell 11.49% year-over-year to -$55.1 million in Q1 2026; TTM through Mar 2026 was -$201.7 million, a 19.67% decrease from a year earlier, with the FY2025 full-year figure at -$196.0 million, up 24.67% from the prior year.
• EBT for Q1 2026 stood at -$55.1 million, down from -$47.5 million in the prior quarter.
• Over the last five years, EBT for RYTM reached as high as -$31.8 million in Q2 2024 and fell as low as -$141.1 million in Q1 2024.
• Historically, EBT has averaged -$51.9 million across 5 years, with a median of -$46.7 million in 2023.
• Across the five-year window, EBT sank 184.15% in 2022 and soared 64.97% in 2025, its largest moves.
• Year by year, EBT stood at -$42.5 million in 2022, then climbed by 2.49% to -$41.4 million in 2023, then declined by 4.69% to -$43.4 million in 2024, then fell by 9.58% to -$47.5 million in 2025, then declined by 15.9% to -$55.1 million in 2026.
• Per Business Quant data, the three most recent EBT figures were -$55.1 million in Q1 2026, -$47.5 million in Q4 2025, and -$52.8 million in Q3 2025.